IMMD Stock UPDATES Immudyne Inc (IMMD) 0.0700 09/11/2014 15:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immudyne Inc (IMMD) 0.0700 $IMMD

ImmuDyne Announces Launch of Clinical Study
GlobeNewswire - Thu Aug 14, 10:59AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has entered into a definitive agreement with the Sedona Institute For Age Management, LLC an affiliate of the Sedona Integrative Medical Clinic, LLC, www.sedonaclinic.com, to complete a clinical study on a new application of the company's patented beta glucan technology.

IMMUDYNE Announces NAYAD Skincare Promotion with Celebrity Who Has It? App for Consumers
GlobeNewswire - Thu Mar 13, 1:21PM CDT
IMMUDYNE, Inc. (OTCQB:IMMD) announced today that it has contracted with Who Has It? App to promote the Company's proprietary, anti-aging skincare line, NAYAD Rejuvenating Serum and Moisturizer.

ImmuDyne Announces Patient Program in Association With Leading Physicians of the Stone Center
GlobeNewswire - Tue Feb 11, 8:15AM CST
ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has established a partnership with leading physicians of the Stone Center of New Jersey for its new nutritional supplements; iNR Wellness and iNR Wellness MD.

ImmuDyne Opens New Online Store for Immune Health and Wellness, iNRStart.com
GlobeNewswire - Wed Jan 08, 8:00AM CST
IMMUDYNE, Inc. (OTCQB:IMMD) announced the opening of the Company's new online store, iNRStart.com (http://www.iNRStart.com), for the retail sale of its new naturally derived nutritional supplements; iNR Wellness(TM), iNR Wellness MD(TM), and iNR Strength(TM).

ImmuDyne to Form Strategic Joint Venture With European Investment Firm for Ex-US Product Launch
GlobeNewswire - Wed Dec 18, 8:00AM CST
ImmuDyne, Inc. (OTCQB:IMMD) (the "Company" and Adiuvo ("Adiuvo" , a life-science and healthcare investment company domiciled in Central Europe, today announced the signing of a Memorandum of Understanding (MOU) to form a strategic Joint Venture ("JV" on all non-US business to anticipate the filing of new patents.

ImmuDyne Announces Affiliate Partnership With Leading Men's Lifestyle Magazine for PFI(TM) Product, Launching This Fall
GlobeNewswire - Wed Jul 17, 8:30AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has signed an affiliate partnership agreement with Kandy Magazine for the promotion of Primed For Immunity(TM) (PFI(TM)), the Company's proprietary hangover prevention product.

ImmuDyne (OTCQB: IMMD) Announces Investor Awareness Campaign, Anticipates Strong Growth
GlobeNewswire - Thu Jun 27, 8:15AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that the Company is launching an investor awareness campaign beginning on July 9, 2013 and continuing throughout 2013. The Company will be implementing strategies and tactics designed to increase market awareness of ImmuDyne and its product portfolio, among strategic investors, institutions and analysts.

ImmuDyne Announces Primed For Immunity(TM) Release at Exclusive, Red Carpet Event in Hollywood, CA With Leading Men's Lifestyle Magazine
GlobeNewswire - Wed Jun 12, 8:30AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that it will be releasing Primed For Immunity(TM) (PFI(TM)), the Company's proprietary peri-/post alcohol product, at an exclusive, red carpet event in Hollywood, CA with a leading men's lifestyle magazine.

ImmuDyne Announces 30% Growth in 6-Month Sales of Cosmetic and Anti-Aging Skin Care Ingredients
GlobeNewswire - Thu Jun 06, 8:44AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that the company has recorded sales growth of 30% in the first 6 months of 2013, as compared to the same period in 2012, in its cosmetic and anti-aging skin care segments.

ImmuDyne to Launch Proprietary Dietary Supplement in the U.S. Alcohol Consumption and Hangover Markets
GlobeNewswire - Tue Jun 04, 8:30AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that the company plans to launch a new, proprietary dietary supplement in the U.S. alcohol consumption and hangover markets later this year.

ImmuDyne Appoints Joseph V. DiTrolio, M.D. as U.S. Chief Medical Officer
GlobeNewswire - Wed May 29, 3:30AM CDT
ImmuDyne, Inc. (OTCQB:IMMD) announced today that the company has appointed Joseph V. DiTrolio, M.D. as the Chief Medical Officer, United States.

Immudyne Announces 15-Month Plan for Growth and April 25th Conference Call
GlobeNewswire - Thu Apr 18, 10:23AM CDT
Immudyne, Inc. (OTCQB:IMMD) announced today that the company plans to execute a 15-Month Sales and Marketing Plan to accomplish increased revenue growth. The company will hold a conference call on Thursday, April 25th at 11 a.m. EDT. To participate in the call, please dial 1-800-816-4164. When prompted, enter the GUEST CODE of 636174#

Immudyne Appoints Karen Kingston, Former Brand Strategist for Johnson & Johnson, Pfizer, and Allergan, to Lead Global Marketing and Sales
GlobeNewswire - Mon Mar 25, 9:42AM CDT
Immudyne, Inc. (OTCQB:IMMD) announced today that Karen Kingston has been appointed as the company's Chief Marketing Officer to lead its global sales and marketing efforts.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading